<DOC>
	<DOCNO>NCT02583477</DOCNO>
	<brief_summary>A Phase Ib II Open-Label , Multi-Center Study MEDI4736 Evaluated Different Combinations Patients Metastatic Pancreatic Ductal Adenocarcinoma</brief_summary>
	<brief_title>Phase Ib/II Study MEDI4736 Evaluated Different Combinations Metastatic Pancreatic Ductal Carcinoma</brief_title>
	<detailed_description>This Phase Ib II open-label , multi-center study evaluate safety , tolerability , pharmacodynamics , antitumor activity MEDI4736 combination chemotherapy novel anticancer agent patient pancreatic ductal adenocarcinoma ( PDAC ) . This study consist 2 independent cohort .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Histologically cytologically confirm metastatic PDAC , 1 prior chemotherapy regimen treatmentnaïve patient 2 . Eastern Cooperative Oncology Group 0 1 3 . At least 1 lesion , previously irradiate , accurately measure baseline ≥10 mm long diameter ( except lymph node , must short axis ≥15 mm ) compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan suitable accurate repeat measurement 4 . MEDI4736 + nabpaclitaxel + gemcitabine chemotherapy cohort : treatmentnaïve patient metastatic PDAC receive previous systemic chemotherapy 5 MEDI4736 + Cohort : Patient receive 1 prior chemotherapy regimen systemic therapy recurrent/metastatic PDAC 6 . Life expectancy ≥ 12 week . 7 . ECOG PS 0 1 8 . Adequate organ bone marrow function 1 . Any concurrent chemotherapy , investigational product , biologic , hormonal therapy cancer treatment . 2 . Receipt last dose approve anticancer therapy within 21 day prior first dose study treatment 3 . Major surgical procedure within 21 day prior first dose IP . 4 . Patients weigh less 30 kg 5 . History leptomeningeal carcinomatosis 6 . Ascites require intervention 7 . Any unresolved toxicity NCI CTCAE Grade ≥2 previous anticancer therapy 8 . Current prior use immunosuppressive medication within 14 day first dose 9 . Brain metastasis spinal cord compression . 10 . Medi4736+AZD5069 Cohort : receive potent moderate cytochrome CYP3A4 inhibitor , potent moderate CYP3A4 inducer , Pgp substrates , BCRP substrates , sensitive CYP2B6 substrate , warfarin coumarin derivative , herbal supplement within 14 day first dose study treatment 11 . Uncontrolled intercurrent illness 12 . Other malignancy within 5 year except noninvasive malignancy 13 . Mean QT interval ≥470 ms 14 . Active infection 15 . Receipt live attenuate vaccine within 30 day prior first dose IP 16 . Female patient pregnant breastfeeding , male female patient reproductive potential employ effective method birth control 17 . Prior exposure immunemediated therapy 18 . Known allergy hypersensitivity IP formulation human monoclonal antibody</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Pancreatic Ductal Adenocarcinoma , PDAC , immunotherapy , PDL1 , AZD5069 , MEDI4736</keyword>
</DOC>